STALICLA
STALICLA, a Swiss clinical stage biotech company leading omics-based drug development for patients with neurodevelopmental disorders (NDDs), announced today the highly successful completion of the phase 1b trials for its lead drug candidate STP1. These clinical data clear the way for a first application of STALICLA’s precision medicine discovery platform in autism spectrum disorders.
The goal of this phase 1b, double-blind, placebo-controlled study was to evaluate the safety, tolerability, and pharmacokinetics of a two-week oral treatment with STP1 in a subgroup of patients with ASD. In addition to showing good safety and tolerability profiles, and dose-dependent target engagement, STP1 treatment resulted in positive signals in clinical markers of neurological and behavioral function, including improved processing speed and crystallized cognition composite.
Speaking about the results, Dr Craig Erickson, M.D. – lead investigator at Cincinnati Children’s Hospital said: “The electrophysiological signals from this study are remarkable and represent the strongest early trial target engagement signals our lab has seen in the autism field. The findings from this project de-risk future larger-scale study given the personalized approach employed to biologically identify specific autistic individuals who may best respond to a treatment prior to study enrollment.”
Baltazar Gomez Mancilla, STALICAL’s CMO, added: “Beyond molecular impact, we are seeing a dose-related decrease of specific abnormal electrophysiological signal in brain regions related to social interaction, working memory and processing speed that may lead to social communication improvement, which is one of the core symptoms of autism. Those results and the prospects of a personalized solution addressing ASD could be a tremendous game-changer for this subgroup of patients representing 20% of ASD population.”
STALICLA drug development relies on DEPI, the AI-driven and clinically validated biotech platform integrating comprehensive metabolomics, whole-genome sequencing, RNA sequencing and a proprietary module to pair patient biological signatures with drug candidates. Using DEPI, STALICLA already proved the clinical validity of several subgroups with neurodevelopmental disorders (Phen1, Phen2, Phen3, Phen5) and their respective tailored treatments, starting with STP1.
Speaking about next steps, Lynn Durham, STALICLA’s CEO & Founder, commented: “We are now turning our sights to the next stage of our growth with some major milestones. First, a multicenter bio sampling study for the enrollment of STP1 phase 2, which should allow us to gather the most comprehensive clinical and multi-omics data set to date in the ASD space. Then, the continuation of STP1 phase 2, increasing treatment duration and dose level, adding a working memory test, and further refining phase 1b's strong findings. Finally, our other milestones will include phase 2 trials for our second precision drug candidate STP2, partnerships’ development and the in-licensing of potential additional compounds. In order to finance this growth, we are currently raising a series B of USD 65M, with target completion Q2-Q3 2022.”
About STALICLA
STALICLA SA is a Swiss clinical stage biopharmaceutical company leading omics-based precision medicine drug development for patients with neurodevelopmental disorders (NDDs), with a first application in autism spectrum disorder (ASD). STALICLA is on a unique mission to identify clinically actionable patient subgroups and develop tailored treatments for those most impaired by their symptoms. Its DEPI technology is the first platform specifically developed to enable precision medicine in complex NDDs. The platform integrates comprehensive metabolomics, whole-genome sequencing, RNA sequencing and its advanced HC match module to pair patient biological signatures with drug candidates. DEPI has reached clinical proof of concept with its first pipeline candidate, STP1. STALICLA is advancing collaborative alliances with strategic third-party pipelines and is rapidly scaling its platform and clinical development activity. For more information, please visit: https://stalicla.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005694/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF to Release Third Quarter 2025 Results on Nov. 4, 202514.10.2025 22:15:00 CEST | Press release
IFF (NYSE:IFF) today announced that it will release its third quarter 2025 earnings results following the market close on Tuesday, Nov. 4, 2025. The management team will host a live webcast on Wednesday, Nov. 5, 2025, at 9:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. View source version on businesswire.com: https://www.businesswire.com/news/home/20251014533502/en/
TRU Simulation and US Aviation Academy sign purchase agreement for five Cessna Skyhawk Veris Virtual Reality Simulators, signifying first fleet order and fixed-wing market debut14.10.2025 20:39:00 CEST | Press release
During the National Business Aviation Association – Business Aviation Convention & Exhibition (NBAA-BACE), TRU Simulation + Training Inc., a Textron Inc.(NYSE:TXT) company, and an affiliate of Textron Aviation Inc., announced an agreement with the US Aviation Academy for its purchase of five of TRU Simulation’s Cessna Skyhawk Veris Virtual Reality (VR) Simulators. This landmark agreement introduces the Veris to the fixed-wing training market and is TRU Simulation’s first fleet order for VR training devices. The US Aviation Academy has the option for a future purchase of ten additional units as part of the agreement, underscoring a shared commitment to advancing pilot training through cutting-edge VR simulation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013144401/en/ TRU Simulation and US Aviation Academy sign purchase agreement for five Cessna Skyhawk Veris Virtual Reality Simulators, signifying first fleet order and
Introducing Lasso: A New Food Tech Company Redefining Consumer Packaged Foods14.10.2025 19:34:00 CEST | Press release
Backed by $6.5M in new funding, Lasso is filling a void in the food industry with its proprietary fiber spinning technology that transforms simple ingredients into clean-label, protein-packed foods. Lasso today announced its official launch and the introduction of its proprietary technology, Lasso SpinTech. This breakthrough system upends the outdated standards of ultra-processed foods using physics to weave together protein and fiber to make previously unattainable new consumer products. With a new $6.5M raise, Lasso is bringing its technology to the world by launching its own brands and licensing to global partners to create a new generation of healthier foods. Guided by CEO Mike Messersmith, the Lasso team spent the past year deploying its commercial-scale technology to create innovative clean-label products including protein-packed snacks and pet food—expanding beyond its first plant-based meat application under the Tender Food brand. Lasso’s latest $6.5M in capital, led by Rhapsod
Rimini Street to Report Third Quarter 2025 Financial Results on October 30, 202514.10.2025 18:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on October 30, 2025. The company will host a conference call and webcast on that date to discuss the third quarter and the 2025 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251014139026/en/ A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasdaq: RMNI), a Russell 2000® Company, is a proven,
Esri’s ArcGIS Maritime to Support Next-Generation S-100 Production Capabilities for Advanced Nautical Charting14.10.2025 18:00:00 CEST | Press release
Hydrographic Offices Can Seamlessly Transition to New Standards While Still Maintaining S-57 Charts Esri, the global leader in geographic information system (GIS) technology, announced new capabilities in ArcGIS Maritime to support production of S-100 compliant nautical charts, marking a major milestone in the evolution of hydrographic data management. Maritime organizations will also be able to generate S-57 charts alongside S-101 charts, which will enable them to more seamlessly leverage GIS. Crucial for supporting the latest spatial data and technologies, the shift to S-100 ready charting will enhance maritime navigation, safety, and situational awareness. The new S-100 series of standards developed by the International Hydrographic Organization (IHO) introduces a modern, extensible framework for electronic navigational charts, bathymetric data, and other marine information products. “The core mission of maritime authorities like hydrographic offices is supporting safe navigation, b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom